BioRestorative Therapies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
$BRTX
Managed Health Care
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 12, 2024
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
|
|
|
|
|
(Address of principal executive offices)
|
|
(Zip code)
|
Registrant's telephone number, including area code (631 ) 760-8100
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act
of 1934 (§240.12b-2 of this chapter):
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 2.02.
|
Result of Operations and Financial Condition.
|
On November 12, 2024, BioRestorative Therapies, Inc. (the “Company”) issued a press release announcing its
financial results for the third quarter ended September 30, 2024 (the “Financial Press Release”). The Financial Press Release also provided a business update and included details with regard to the conference call to be held to discuss the third
quarter results and business update. A copy of the Financial Press Release is furnished as Exhibit 99.1 hereto.
The information contained in the Financial Press Release is summary information that should be considered in the context of the
Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time.
The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act
of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 7.01
|
Regulation FD Disclosure.
|
See Item 2.02 above.
On November 13, 2024, the Company issued a press release (the “Presentation Press Release”) announcing that additional
preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease would be presented by Francisco Silva, the Company’s Vice President of Research and Development, at the
Orthopaedic Research Society (ORS) Philadelphia Spine Research Society (PSRS) 7th International Spine Research Symposium, taking place November 10-14, 2024 in Skytop, Pennsylvania. The presentation took place on November 13, 2024. In the
Presentation Press Release, the Company also announced that at the conference call to be held to discuss the Company’s third quarter results and business update, the Company will also review the BRTX-100 presentation. A copy of the Presentation Press
Release is furnished as Exhibit 99.2 hereto. At the symposium certain presentation materials (the “Presentation Materials”) may be utilized by Mr. Silva. A copy of the Presentation Materials is furnished as Exhibit 99.3 hereto. The Company may use
the Presentation Materials, possibly with modification, in other presentations to current and potential investors, lenders, creditors, insurers, vendors, customers, employees and others with an interest in the Company and its business
The information contained in the Presentation Press Release and the Presentation Materials is summary information that should be
considered in the context of the Company’s filings with the Securities and Exchange Commission and other public announcements that the Company may make by press release or otherwise from time to time.
The information in the Financial Press Release, the Presentation Press Release and the Presentation Materials is being
furnished, not filed, pursuant to this Item 7.01. Accordingly, the information in the Financial Press Release, the Presentation Press Release and the Presentation Materials will not be incorporated by reference into any registration statement filed
by the Company under the Securities Act unless specifically identified therein as being incorporated therein by reference. The furnishing of the information in this Current Report on Form 8-K with respect to the Financial Press Release, the
Presentation Press Release and the Presentation Materials is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K with respect to the Financial Press Release,
the Presentation Press Release and the Presentation Materials is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Number
|
Description
|
|
99.1
|
Press release, dated November 12, 2024, issued by BioRestorative Therapies, Inc.
|
|
99.2
|
Press release, dated November 13, 2024, issued by BioRestorative Therapies, Inc.
|
|
99.3
|
Presentation Materials
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| Company Name | |||
|
Dated: November 13, 2024
|
By:
|
/s/ Robert Kristal |
|
| Robert Kristal |
|||
| Chief Financial Officer |
|||